ASZ1 Stock Overview
Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Alimera Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.23 |
| 52 Week High | US$3.83 |
| 52 Week Low | US$1.47 |
| Beta | 1.2 |
| 1 Month Change | -3.15% |
| 3 Month Change | -8.12% |
| 1 Year Change | 113.58% |
| 3 Year Change | -56.42% |
| 5 Year Change | -73.16% |
| Change since IPO | -97.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| ASZ1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.0% | 2.6% | 2.0% |
| 1Y | 113.6% | -22.6% | 5.9% |
Return vs Industry: ASZ1 exceeded the German Pharmaceuticals industry which returned -22.6% over the past year.
Return vs Market: ASZ1 exceeded the German Market which returned 6% over the past year.
Price Volatility
| ASZ1 volatility | |
|---|---|
| ASZ1 Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ASZ1 has not had significant price volatility in the past 3 months.
Volatility Over Time: ASZ1's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 157 | Rick Eiswirth | alimerasciences.com |
Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
Alimera Sciences, Inc. Fundamentals Summary
| ASZ1 fundamental statistics | |
|---|---|
| Market cap | €172.76m |
| Earnings (TTM) | -€19.86m |
| Revenue (TTM) | €74.96m |
2.3x
P/S Ratio-8.7x
P/E RatioIs ASZ1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASZ1 income statement (TTM) | |
|---|---|
| Revenue | US$80.75m |
| Cost of Revenue | US$10.84m |
| Gross Profit | US$69.92m |
| Other Expenses | US$91.31m |
| Earnings | -US$21.39m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -0.41 |
| Gross Margin | 86.58% |
| Net Profit Margin | -26.49% |
| Debt/Equity Ratio | 139.7% |
How did ASZ1 perform over the long term?
See historical performance and comparison